Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Input metadata referenced "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2001
Status: Development stage enterprise focused on proprietary pulmonary delivery technologies (MSI, ADDS, UPDAS). The company has generated minimal revenue and sustained significant net operating losses since inception in 1986.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 | Inception to Mar 31, 2001 |
|---|---|---|---|
| Total Revenues | $180,747 | $121,170 | $2,446,697 |
| Net Loss | $(1,580,410) | $(1,457,090) | $(79,366,599) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.05) | $(8.22) |
| Cash and Cash Equivalents (End of Period) | $2,381,084 | $3,487,892 | N/A |
| Net Cash Used in Operating Activities | $(708,273) | $(1,818,690) | $(71,380,123) |
| Total Liabilities | $5,525,075 | N/A | N/A |
| Stockholders' Equity (Deficiency) | $(1,917,822) | N/A | N/A |
Debt and Liquidity: The company holds a $2,000,000 convertible promissory note. Cash decreased by $660,864 during the quarter. The company has raised approximately $75.6 million since inception but requires substantial additional capital to continue operations.
Material Changes vs. Prior Period
- Revenue Increase: Contract research revenue increased by $59,577 (49%) compared to Q1 2000, driven by higher costs associated with MSI device development and testing prior to Phase III trials.
- Expense Growth: Research and Development (R&D) expenses rose by $143,750 to $1,045,773, reflecting development costs for unit-dose and MSI steroid products. General and Administrative expenses increased by $63,545 due to higher consulting and legal fees.
- Cash Flow Improvement: Net cash used in operating activities decreased significantly to $708,273 from $1.8 million in the prior year, largely due to a $1.0 million milestone advance receivable collected from Zambon.
- Equity Position: The accumulated deficit grew to $(82.8) million, and the net capital deficiency increased to $(1.9) million.
Outlook, Risks, and Management Commentary
Outlook and Capital Needs: Management states the company will require substantial additional capital before recognizing significant cash flow from operations. Funding is expected to come from equity/debt offerings, out-licensing, and collaboration agreements. There is no assurance that additional funds will be available on favorable terms.
Key Agreements:
- Zambon: Received a $1.0 million milestone advance in January 2001 for technical feasibility of inhaled steroid delivery. Future milestones are required to recognize this as revenue; otherwise, it must be repaid.
- Elan: Holds a commitment to purchase up to $4.0 million of Series E Preferred Stock, with $3.0 million remaining outstanding.
Risks and Contingencies:
- Financing Risk: Failure to obtain additional financing may force the company to delay or eliminate R&D programs.
- Commercialization Risk: No assurance that technologies will be successfully commercialized or generate sufficient revenue.
- Regulatory Risk: Products must meet regulatory standards and receive approval; failure to do so would halt commercialization.
- Listing Risk: Failure to meet American Stock Exchange listing guidelines could impair the ability to raise capital.
Investor Verification Checklist
- Verify the status of the $1.0 million milestone advance from Zambon and the specific future milestones required to recognize it as revenue.
- Confirm the remaining $3.0 million commitment from Elan for Series E Preferred Stock and the timeline for drawdown.
- Assess the timeline and funding requirements for the Phase III MSI-albuterol clinical trials.
- Review the terms of the $2.0 million convertible promissory note with Elan, including interest rates and conversion triggers.
- Monitor cash burn rate against the current cash balance of $2.38 million to estimate runway without new financing.